Yael N. Kusne, M.D., Ph.D.

Open

• Clonal Hematopoiesis (CH) and Hematological Toxicity after Radiotheranostic Agents in Solid Tumor Patients (CHIP) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The overall objective of this project is to combine robust clinical data (e.g. prior chemotherapy or radiation exposure, cumulative radiotheranostic dose) with geneticclonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in radiotheranostic treated solid tumor patients.

• Pre-myeloid Cancer and Bone Marrow Failure Clinic Study Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to test a new technology called Next Generation Sequencing (NGS) that may help identify this risk associated with precursor conditions and the likelihood that they will change into overt blood and bone marrow cancers. NGS is a procedure that looks at relevant cancer associated genes and what they do.